Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia: Comparing Outcome and Study Discontinuation of Groups of Participants in the Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial

Lyliana G. Nasib, PhD; Inge Winter-van Rossum, PhD; Nicolaas P. A. Zuithoff, PhD; Zimbo S. R. M. Boudewijns, PhD; Stefan Leucht, MD, PhD; René S. Kahn, MD, PhD

J Clin Psychiatry 2023;84(3):22m14531

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Author Affiliations

Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands
Corresponding author: Lyliana G. Nasib, PhD, University Medical Center Utrecht, Heidelberglaan 100, PO Box 85500, 3508 GA Utrecht ([email protected]).
Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands
Department of Psychiatry, Icahn School of Medicine, Mount Sinai, New York, New York
Department of Biostatistics and Research Support, University Medical Center Utrecht, Utrecht, The Netherlands
Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands
Technical University of Munich, School of Medicine, Department of Psychiatry and Psychotherapy, Munich, Germany
Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands
Department of Psychiatry, Icahn School of Medicine, Mount Sinai, New York, New York

References (30)

Wong JJ, Jones N, Timko C, et al. Exclusion criteria and generalizability in bipolar disorder treatment trials. Contemp Clin Trials Commun. 2018;9:130–134. PubMed CrossRef
Humphreys K. A review of the impact of exclusion criteria on the generalizability of schizophrenia treatment research. Clin Schizophr Relat Psychoses. 2017;11(1):49–57. PubMed CrossRef
Hoertel N, Le Strat Y, Lavaud P, et al. Generalizability of clinical trial results for bipolar disorder to community samples: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2013;74(3):265–270. PubMed CrossRef
Karcher H, Fu S, Meng J, et al; GetReal Consortium Work Package 2. The “RCT augmentation”: a novel simulation method to add patient heterogeneity into phase III trials. BMC Med Res Methodol. 2018;18(1):75. PubMed CrossRef
Taipale H, Schneider-Thoma J, Pinzón-Espinosa J, et al. Representation and outcomes of individuals with schizophrenia seen in everyday practice who are ineligible for randomized clinical trials. JAMA Psychiatry. 2022;79(3):210–218. PubMed CrossRef
Boter H, Derks EM, Fleischhacker WW, et al; EUFEST Study Group. Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry. 2010;71(1):58–65. PubMed CrossRef
Riedel M, Leucht S, Rüther E, et al. Critical trial-related criteria in acute schizophrenia studies. Eur Arch Psychiatry Clin Neurosci. 2012;262(2):151–155. PubMed CrossRef
Sher L, Kahn RS. Suicide in schizophrenia: an educational overview. Medicina (Kaunas). 2019;55(7):361. PubMed CrossRef
Hunt GE, Large MM, Cleary M, et al. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: Systematic review and meta-analysis. Drug Alcohol Depend. 2018;191(August):234–258. PubMed CrossRef
Winklbaur B, Ebner N, Sachs G, et al. Substance abuse in patients with schizophrenia. Dialogues Clin Neurosci. 2006;8(1):37–43. PubMed CrossRef
Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365(9453):82–93. PubMed CrossRef
Nordon C, Bovagnet T, Belger M, et al; IMI GetReal WP2 group. Trial exclusion criteria and their impact on the estimation of antipsychotic drugs effect: a case study using the SOHO database. Schizophr Res. 2018;193:146–153. PubMed CrossRef
Zarin DA, Young JL, West JC. Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network. Soc Psychiatry Psychiatr Epidemiol. 2005;40(1):27–35. PubMed CrossRef
Leucht S, Winter-van Rossum I, Heres S, et al. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophr Bull. 2015;41(3):549–558. PubMed CrossRef
Kahn RS, Winter van Rossum I, Leucht S, et al; OPTiMiSE study group. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry. 2018;5(10):797–807. PubMed CrossRef
Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22–33, quiz 34–57. PubMed
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. PubMed CrossRef
Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–449. PubMed CrossRef
Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry suppl. 1993;163(22):39–44. PubMed CrossRef
Guy W. Clinical Global Impression (CGI). ECDEU Assess Man Psychopharmacol. 1976:125–126. https://www.psywellness.com.sg/docs/CGI.pdf.
Nasrallah H, Morosini P, Gagnon DD. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res. 2008;161(2):213–224. PubMed CrossRef
Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. Springer Series in Statistics. Vol. 608. New York: Springer; 2001.
IBM. IBM SPSS Statistics Software for Windows, Version 25. IBM. doi:10.1016/j.jchf.2014.02.009.
SAS Institute Inc. Cary, NC U. Sas 9.4. Cary, NC: SAS Inst Inc; 2017.
Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand. 2005;112(2):141–148. PubMed CrossRef
Austad G, Joa I, Johannessen JO, et al. Gender differences in suicidal behaviour in patients with first-episode psychosis. Early Interv Psychiatry. 2015;9(4):300–307. PubMed CrossRef
Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–1277. PubMed CrossRef
FDA. Guidance for Industry: Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials. Center for Drug Evaluation and Research. FDA website. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-suicidal-ideation-and-behavior-prospective-assessment-occurrence-clinical-trials.
Pelizza L, Pellegrini C, Quattrone E, et al. Suicidal thinking and behavior in first episode schizophrenia: findings from the 24-month follow-up of the “Parma Early Psychosis” program. Arch Suicide Res. 2020;26(2):656–676. PubMed CrossRef
Cotton SM, Lambert M, Schimmelmann BG, et al. Differences between first episode schizophrenia and schizoaffective disorder. Schizophr Res. 2013;147(1):169–174. PubMed CrossRef